Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
QIMC Defines Multiple New Hydrogen Hot Zones in Nova Scotia, Reports Stronger Preliminary DDH-26-05 Hydrogen Readings and Triples 2026 Nova Scotia Exploration Program Across a 43-km District-Scale Corridor
